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Abstract: Chronic respiratory diseases involve a heterogenous
group of diseases, including, chronic obstructive pulmonary disease
(COPD), asthma, sleep apnea syndrome, pulmonary hypertension,
and many occupational diseases. They affect more than one billion
people worldwide. Their medical, social, and economic impacts are
heavy, especially in developing countries such as Middle East and
North Africa countries, where they represent a public health prob-
lem. They are essentially represented by COPD, asthma, and allergic
diseases. Chronic respiratory diseases are increasing in frequency,
morbidity, and mortality. In addition, their economic and social
impact is increasing rapidly in this region. Main risk factors are
represented by tobacco smoking and exposure to biomass fuel.
Smoking prevention and standardized management programs for
asthma and COPD are now available but prompt actions are needed
to make them more effective in this region and thus avoid an adverse
impact on national economic development.
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INTRODUCTION
Chronic respiratory diseases (CRD), essentially chronicobstructive pulmonary disease (COPD), asthma, respira-
tory allergies, and occupational lung diseases represent a
major public health problem in developing countries includ-
ing the Middle East and North Africa (MENA) countries.
This is because of their high frequency and their social and
economic impacts. Fortunately, most CRD are preventable
and treatable. Several guidelines such as the global initiative
for chronic obstructive lung diseases (GOLD), global initia-
tive for asthma (GINA), and allergic rhinitis and its impact on
asthma (ARIA) are now very helpful to improve the manage-
ment of CRD. We try to clarify the burden and trend of CRD
and their economic impact in MENA countries from available
data in the literature.
PREVALENCE OF MAIN CRD (COPD AND
ASTHMA) IN MENA AND RISK FACTORS
Millions of people of all ages suffer from preventable
CRD and respiratory allergies in MENA region. CRD are
increasing in prevalence in all ages, but there are considerable
differences in prevalence between regions.1
COPD
Although COPD is one of the leading causes of mor-
tality and morbidity worldwide, epidemiological data on
COPD are very limited, especially in MENA countries. In
1990, the World Health Organization evaluated the global
prevalence of COPD to be 9.33 per 1000 for men and 7.33 per
1000 for women.2
In middle-income countries, such as in MENA, COPD
is emerging as public health problem. However, the disease is
certainly under diagnosed. In fact, the diagnosis is made
when it becomes clinically apparent and in late stage.2
In 2001, the prevalence of COPD in Africa was esti-
mated 179/100,000 and 301/100,000 in eastern Mediterra-
nean countries. This prevalence was low compared with
America and Europe.3
In Tunisia, prevalence of COPD is estimated as 3.8%
(1.1% in women and 6.6% in men) and more than 2000
patients suffer from chronic respiratory failure.4 In Algeria
prevalence of COPD more than 40 years was 125/100,000
people in 1990.2
COPD affects men more frequently than women, be-
cause of less frequent smoking in women. It usually appears
after 40 years of age, and increases in frequency with age.
Main risk factors for CRD in MENA are represented
by tobacco smoke, second hand tobacco smoke, and other
indoor and outdoor air pollutants. In This region, COPD
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affects people with low socioeconomic status. In fact, it
has been demonstrated that smoking is more prevalent in
illiterate people.2,5
Tobacco smoking is established to be the major risk
factor of COPD. In Tunisia, according to the study of public
health institute, tobacco consumption was reported in 30, 4%
of studied population and smoking was 10 times more fre-
quent in men than women.5,6
In Middle East and Mediterranean countries, smoking
in men is varying between 20% in Iran and 63% in Turkey. In
Lebanon, more than 30% of women are smokers. In the
other countries of the region, smoking concerns less than
10% of women.5
In MENA, CRD are also a result of environmental
factors such as indoor air pollution from biomass fuel, used
for cooking and heating, which appears to contribute to
COPD in women in MENA countries, but less frequent
comparing to African countries.7,8 An estimated 25–45% of
patients with COPD are not smokers but exposed to smoke
from biomass, suggesting that exposure to biomass smoke
contributes largely in social and economic impact of CRD.8
In Turkey, the prevalence of COPD was estimated to
18.1% in current smokers more than 40 years of age and was
4.5% among younger smokers; 25.5% of the women and
57.2% of the men were current smokers. Biomass exposure
was significantly common among female patients living in
rural areas (54.5%). In the genesis of COPD, the relative risk
ratio of cigarette smoke was found to be 3.4 and 3.3 times
higher than biomass exposure and occupational exposure.9
In general, the prevalence of COPD in MENA is
increasing. In women it is also increasing not only because of
exposure to biomass fuels in these countries, but also because
of the growing habit of cigarette smoking in women.
Asthma
The prevalence of asthma increases as communities
adopt modern life styles and become urbanized. The Euro-
pean Community Respiratory Health Survey (ECRHS) esti-
mated the prevalence of asthma in adults in Mediterranean
countries between 1 and 4%.10 According to the international
Study of Asthma and Allergies in Childhood (ISAAC) in
1998, asthma prevalence was evaluated to 16.5 and 10.7%,
respectively, in North Africa and East Mediterranean.11 How-
ever, we admit differences between regions because of their
social and cultural habits (Table 1).
In Jordan, prevalence of asthma in children is moderate,
with no significant difference between the Amman city group
and Bedouins (8.8 vs. 9.5%). Authors concluded that there is
a 2-fold increase in the prevalence of asthma in Jordan in the
last 10 years.12
In another recent cross-sectional epidemiological sur-
vey of asthma, conducted in the Maghreb countries, the
overall prevalence of asthma in the general population of
Maghreb countries was estimated to be 3.6%, with no rele-
vant difference apparent between the 3 countries (Algeria,
Morroco, and Tunisia). This corresponds to a moderate prev-
alence rate from a worldwide perspective, in accordance to
rating of these countries in the most recent GINA burden of
asthma report. Highest rates were observed in the densely
populated and urbanized regions.14
GLOBAL MORTALITY, DALYS, AND ECONOMIC
COSTS OF COPD IN MENA
COPD is a major cause of chronic morbidity and
mortality and represents a substantial economic and social
burden throughout the world. It is the 5th leading cause of
death worldwide and further increases in its prevalence and
mortality are expected in the coming decades, being the third
cause of death in the world by 2020.1 In low- and middle-
income countries, COPD is also one of the 10 leading causes
of death.15
In Africa, mortality resulting from COPD is globally
estimated to 18.1/100,000 in 2001, similar rate (18.3/100,000)
was found in East Mediterranean countries.3 This increase in
COPD mortality is because of increases in smoking, particularly
in women.
Burden of CRD can also be measured in disability-
adjusted life years (DALYs). The world bank estimated
that COPD and asthma were responsible for 2.2% of the
global burden of disease in East Mediterranean countries
in 1999.1 Worldwide, COPD is expected to move up from
the 12th leading cause of DALYs in 1990 to the 5th
leading cause in 2020.1,16
General Cost of CRD in MENA countries remains
poorly recognized and difficult to estimate because of lack of
data from these countries. However, it is expected that direct
costs in COPD are heavy and represent more than half of the
total cost, in contrast with asthma in which indirect costs are
major.
CONCLUSION
Impact of CRD, particularly COPD and asthma in MENA
is heavy and needs more actions especially to increase aware-
ness and understanding of CRD and their comorbidities among
healthcare workers, healthcare providers, and governments.
This heavy impact is due at primary level to an under
diagnosis of CRD, especially COPD, which might be sus-
pected from patient history, clinical symptoms, and con-
firmed by spirometry.
Effective plans such as education programs and smok-
ing cessation programs are needed to make an early and
accurate diagnosis and hence effective management for pa-
tients with CRD. National programs for main CRD (COPD
and asthma) have to be developed in these countries to
standardize their management.
TABLE 1. Prevalence of Recent Wheeze and Diagnosed









Saudi Arabia 11.2 12.1
Kuwait 16.2 16.8
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We are still faced with paucity of epidemiological data
in MENA countries. The BOLD (Burden of Obstructive Lung
Disease) initiative is designed to provide country-specific data
on the prevalence, social, and economic burden of COPD.17
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